<?xml version="1.0" encoding="UTF-8"?>
<p>Further structural modifications of Donecopride allowed the discovery of other interesting compounds endowed with a multitarget profile, such as a dual 5-HT
 <sub>4</sub>R partial agonist and 5-HT
 <sub>6</sub>R antagonist, with no activity on AChE (
 <bold>32</bold>, 
 <xref ref-type="fig" rid="fig10">Figure 10</xref>) [
 <xref rid="B82" ref-type="bibr">82</xref>] useful to study the serotoninergic role in AD, or a dual inhibitor of AChE and modulator of 
 <italic>σ</italic>1 receptor (
 <italic>σ</italic>1R) (
 <bold>33</bold>, 
 <xref ref-type="fig" rid="fig10">Figure 10</xref>), that will be subject of discussion in the following paragraph as a more recent combination to address AD-related dysfunctions.
</p>
